Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) was upgraded by equities research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report released on Friday.

A number of other analysts have also issued reports on the company. Zacks Investment Research upgraded Bellerophon Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 price target for the company in a research note on Tuesday, July 11th. HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of Bellerophon Therapeutics in a research note on Wednesday.

Bellerophon Therapeutics (NASDAQ BLPH) traded up 1.75% during mid-day trading on Friday, hitting $1.16. The stock had a trading volume of 220,884 shares. The firm’s market cap is $41.19 million. Bellerophon Therapeutics has a 12-month low of $0.43 and a 12-month high of $1.98. The company has a 50-day moving average of $1.20 and a 200-day moving average of $1.36.

Bellerophon Therapeutics (NASDAQ:BLPH) last announced its earnings results on Monday, August 7th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.03. Analysts expect that Bellerophon Therapeutics will post ($1.12) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Bellerophon Therapeutics, Inc. (BLPH) Upgraded to “Sell” at ValuEngine” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/09/bellerophon-therapeutics-inc-blph-upgraded-to-sell-at-valuengine.html.

Large investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. acquired a new position in Bellerophon Therapeutics in the first quarter worth about $125,000. Renaissance Technologies LLC grew its stake in Bellerophon Therapeutics by 99.7% in the first quarter. Renaissance Technologies LLC now owns 477,400 shares of the biotechnology company’s stock worth $711,000 after purchasing an additional 238,300 shares in the last quarter. Vanguard Group Inc. grew its stake in Bellerophon Therapeutics by 52.6% in the second quarter. Vanguard Group Inc. now owns 612,641 shares of the biotechnology company’s stock worth $821,000 after purchasing an additional 211,111 shares in the last quarter. Finally, Susquehanna International Group LLP acquired a new position in Bellerophon Therapeutics in the second quarter worth about $1,316,000. Institutional investors and hedge funds own 45.85% of the company’s stock.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.